Produits et Technologies Technologies et Procédés 6 Vaccins candidats pour le COVID-19: où on en est?6 Vaccins candidats pour le COVID-19: où on en est?
- Détails
- Publié le mercredi 8 avril 2020 13:48
- Écrit par Fatima Belmehdi
Le développement d'un vaccin efficace nécessite en temps normal 10 à 15 ans de recherche. Mais face au caractère pandémique de cette maladie, un effort international a été déployé pour trouver un vaccin en 18 mois.
En Avril 2020, l'OMS a recencé une soixantaine de vaccins potentiels pour lutter contre le COVID-19. Ce document considère seulement deux vaccins en phase clinique à savoir l'américain "mRNA-1273" et le chinois "Adenovirus Type 5 Vector". Cependant, une analyse des données du registre américain Clinicaltrials révèle qu'au moins six de ces vaccins sont déjà en phase 1. Ces derniers sont décrits dans le tableau suivant:
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
Age |
Phase |
Start Date |
Completion Date |
|
Safety and Immunity of Covid-19 aAPC Vaccine |
Treat and Prevent Covid-19 Infection |
Biological: Pathogen-specific aAPC |
Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital |
6 Months to 80 Years (Child, Adult, Older Adult) |
I |
February 15, 2020 |
December 31, 2024 |
|
|
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 |
COVID-19 |
Biological: bacTRL-Spike |
Symvivo Corporation |
19 Years to 55 Years (Adult) |
I |
April 30, 2020 |
December 31, 2021 |
|
|
A Study of a Candidate COVID-19 Vaccine (COV001) |
Coronavirus |
Biological: ChAdOx1 nCoV-19|Biological: MenACWY Placebo |
University of Oxford |
18 Years to 55 Years (Adult) |
I/II |
April 2020 |
May 2021 |
|
|
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine |
Pathogen Infection Covid-19 Infection |
Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs |
Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital |
6 Months to 80 Years (Child, Adult, Older Adult) |
I/II |
March 24, 2020 |
December 31, 2024 |
|
|
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection |
Corona Virus Infection|Immunisations |
Biological: mRNA-1273 |
National Institute of Allergy and Infectious Diseases (NIAID) |
18 Years to 55 Years (Adult) |
I |
March 3, 2020 |
June 1, 2021 |
|
|
A Phase I Clinical Trial in 18-60 Adults (APICTH) |
COVID-19 |
Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) |
CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital |
18 Years to 60 Years (Adult) |
I |
March 16, 2020 |
December 20, 2022 |
|
|
Safety, Tolerability and Immunogenicity of INO-4800 in Healthy Volunteers |
Coronavirus Infection |
Drug: INO-4800|Device: CELLECTRA® 2000 |
Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI) |
18 Years to 50 Years (Adult) |
I |
April 2020 |
November 2020 |
Source : clinicaltrials.gov
Pour en savoir plus
DRAFT landscape of COVID-19 candidate vaccines – 4 April 2020
Calendrier
| Lun | Mar | Mer | Jeu | Ven | Sam | Dim |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
| |||||